Scarica l'app Stockscreener
42.39
0.19%
0.08
Dopo l'orario di chiusura:
42.68
0.29
+0.68%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$42.31
Aprire:
$42.32
Volume 24 ore:
1.72M
Relative Volume:
0.74
Capitalizzazione di mercato:
$5.86B
Reddito:
$181.74M
Utile/perdita netta:
$-143.97M
Rapporto P/E:
-30.50
EPS:
-1.39
Flusso di cassa netto:
$9.60M
1 W Prestazione:
+11.55%
1M Prestazione:
+22.91%
6M Prestazione:
+205.18%
1 anno Prestazione:
+120.44%
Intervallo 1D:
$41.31
$43.69
Intervallo di 1 settimana:
$38.63
$43.69
Portata 52W:
$9.57
$43.69
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
42.39 | 5.85B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
How sentiment analysis helps forecast Arrowhead Pharmaceuticals Inc.Portfolio Risk Summary & Real-Time Sentiment Analysis - newser.com
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockMarket Risk Report & Safe Entry Momentum Tips - newser.com
Why analysts remain bullish on Arrowhead Pharmaceuticals Inc. stockLong Setup & Detailed Earnings Play Alerts - newser.com
Why Arrowhead Pharmaceuticals Inc. is moving todayQuarterly Trade Report & Expert Approved Momentum Ideas - newser.com
Best data tools to analyze Arrowhead Pharmaceuticals Inc. stockQuarterly Performance Summary & Accurate Trade Setup Notifications - newser.com
Will Arrowhead Pharmaceuticals Inc. stock split again soonEarnings Beat & Accurate Technical Buy Alerts - newser.com
Can Arrowhead Pharmaceuticals Inc. stock reach $100 price targetEarnings Overview Report & Daily Technical Stock Forecast Reports - newser.com
How to build a dashboard for Arrowhead Pharmaceuticals Inc. stockPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com
How to escape a deep drawdown in Arrowhead Pharmaceuticals Inc.Market Activity Report & High Accuracy Investment Signals - newser.com
Is Arrowhead Pharmaceuticals Inc. stock attractive for growth ETFsPortfolio Return Report & Entry and Exit Point Strategies - newser.com
What makes Arrowhead Pharmaceuticals Inc. (HDP1) stock appealing to growth investorsQuarterly Portfolio Summary & Weekly Setup with High ROI Potential - newser.com
Published on: 2025-11-01 03:37:05 - newser.com
Will Arrowhead Pharmaceuticals Inc. stock benefit from upcoming earnings reportsWeekly Investment Report & Stock Portfolio Risk Management - newser.com
Combining price and volume data for Arrowhead Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - newser.com
Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Severe Hypertriglyceridemia - MSN
Arrowhead Pharmaceuticals Advances in FSHD1 Treatment with ARO-DUX4 Study - MSN
Is Arrowhead Pharmaceuticals Inc. stock cheap at current valuation2025 Top Gainers & Verified Entry Point Signals - newser.com
How buybacks impact Arrowhead Pharmaceuticals Inc. stock value2025 Trading Recap & Intraday High Probability Setup Alerts - newser.com
Published on: 2025-10-31 04:03:58 - newser.com
Advanced analytics toolkit walkthrough for Arrowhead Pharmaceuticals Inc.Market Performance Report & Verified Momentum Watchlists - newser.com
Is Arrowhead Pharmaceuticals Inc. showing signs of accumulationJuly 2025 Decliners & Short-Term Trading Opportunity Alerts - newser.com
Can Arrowhead Pharmaceuticals Inc. stock sustain revenue growth2025 Performance Recap & Real-Time Chart Breakout Alerts - newser.com
Why Arrowhead Pharmaceuticals Inc. (HDP1) stock signals breakout potentialJuly 2025 Breakouts & Free Reliable Trade Execution Plans - newser.com
Can Arrowhead Pharmaceuticals Inc. stock hit analyst price targetsLong Setup & Technical Pattern Alert System - newser.com
Published on: 2025-10-30 23:19:07 - newser.com
Arrowhead Pharmaceuticals Advances in SCA2 Treatment with ARO-ATXN2 Study - TipRanks
Arrowhead Pharmaceuticals, Inc. (ARWR) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Arrowhead Pharmaceuticals Advances ARO-DM1 Study for Myotonic Dystrophy - TipRanks
Cwm LLC Has $180,000 Stake in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Published on: 2025-10-30 00:34:36 - newser.com
Is Arrowhead Pharmaceuticals Inc. (HDP1) stock dividend growth reliableShort Setup & Capital Efficient Trade Techniques - newser.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 12-Month HighStill a Buy? - MarketBeat
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - Yahoo! Finance UK
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):